Sinusoidal Obstruction Syndrome (SOS), also referred to as hepatic veno-occlusive disease
(VOD), is rare but serious complication of allogeneic stem cell transplantation (allo-SCT).
Defibrotide is the only FDA approved therapy to treat SOS and has significantly improved
outcomes. When applied early, SOS symptoms often quickly improve and an abbreviated course
can be applied. This study is looking at an abbreviated 5 day course of defibrotide in those
patients with a complete response to therapy with the primary outcome being day 100 overall
survival as compared to history data.